Minimal Residual Disease Testing Infrastructure in Multiple Myeloma: Guidance for Clinical Trial and Routine Practice Use in Canada

Authors: Mian, Hira S ^{1, ⁎}, Visram, Alissa ², Shih, Steven Chun-Min ³, Trudel, Suzanne ³, Hay, Annette E ⁴, LeBlanc, Richard ⁵, Sebag, Michael ⁶, Kaedbey, Rayan ⁷, Stakiw, Julie ⁸, Sandhu, Irwindeep ⁹, Phua, Chai W ¹⁰, Kuruvilla, Philip G ¹¹, Othman, Ibraheem ¹², Quest, Graeme ⁴, McMullen, David ¹³, Colasurdo, Gabriele ^{14, ⁎⁎}, Kotb, Rami ¹⁵, Venner, Christopher P ¹⁶

Source: In Clinical Lymphoma, Myeloma and Leukemia January 2025

Determining the Associations Between Glucocorticoid Use During Hematologic Chemotherapy Treatment and New-onset Diabetes and Hyperglycemia and Mortality: A Population-based Cohort Study

Authors: Moore-Vasram, Sarah, Sawhney, Monakshi, Houlden, Robyn L., Groome, Patti A., Goldie, Catherine, Li, Wenbin, Hay, Annette E., Tranmer, Joan

Source: In Canadian Journal of Diabetes April 2024 48(3):195-203

A Phase II, Open-Label Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma

Authors: Stakiw, Julie, Kodad, Shruthi, LeBlanc, Richard, Sebag, Michael, Hay, Annette E., Kukreti, Vishal, Côté, Julie, Camacho, Fernando, Fu, Molei, Gul, Engin, Reece, Donna

Source: Clinical lymphoma, myeloma & leukemia. 23(7):484-490

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100193423013.0x000001&indx=1&recIds=ETOCvdc_100193423013.0x000001

A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612

Authors: Assouline, Sarit, Michaelis, Laura C., Othus, Megan, Hay, Annette E., Walter, Roland B., Jacoby, Meagan A., Schroeder, Mark A., Uy, Geoffrey L., Law, Lisa Y., Cheema, Faisal, Sweet, Kendra L., Asch, Adam S., Liu, Jijun (Jane), Moseley, Anna B., Maher, Tracy, Kingsbury, Laura L., Fang, Min, Radich, Jerald, Little, Richard F., Erba, Harry P.

Source: Leukemia & lymphoma. 64(2):473-477

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100175112165.0x000001&indx=1&recIds=ETOCvdc_100175112165.0x000001

A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia

Authors: Cheung, Matthew C., Mittmann, Nicole, Owen, Carolyn, Abdel-Samad, Nizar, Fraser, Graeme A.M., Lam, Selay, Crump, Michael, Sperlich, Catherine, van der Jagt, Richard, Prica, Anca, Couban, Stephen, Woyach, Jennifer A., Ruppert, Amy S., Booth, Allison M., Mandrekar, Sumithra J., McDonald, Gail, Shepherd, Lois E., Yen, Hope, Chen, Bingshu E., Hay, Annette E.

Source: In Clinical Lymphoma, Myeloma and Leukemia November 2021 21(11):766-774

Validation, Implementation, and Clinical Impact of the Oncomine Myeloid Targeted-Amplicon DNA and RNA Ion Semiconductor Sequencing Assay

Authors: Ferrone, Christina K., Wong, Henry, Semenuk, Laura, Werunga, Barnaba, Snetsinger, Brooke, Zhang, Xiao, Zhang, Grace, Lui, Janet, Richard-Carpentier, Guillaume, Crocker, Susan, Good, David, Hay, Annette E., Quest, Graeme, Carson, Nancy, Feilotter, Harriet E., Rauh, Michael J.

Source: In The Journal of Molecular Diagnostics October 2021 23(10):1292-1305

A descriptive cost‐analysis of MYX.1/MCRN003, a phase 2 clinical trial evaluating high‐dose weekly carfilzomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma

Authors: Monteith, Bethany E., Venner, Christopher P., Cheung, Matthew C., Pater, Joe, Shepherd, Lois, Richardson, Harriet, Reece, Donna, Gul, Engin, Lalancette, Marc, Castonguay, Vincent, Kukreti, Vishal, Tiedemann, Rodger, Phua, Chai, Bhella, Sita, Dudebout, Jill, Sherry, Max, Yen, Hope, Chen, Bingshu E., Hay, Annette E.

Source: European journal of haematology. 107(3):333-342

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100124887418.0x000001&indx=1&recIds=ETOCvdc_100124887418.0x000001

Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed/refractory multiple myeloma: Final results from the MCRN‐003/MYX.1 single arm phase II trial

Authors: Venner, Christopher P., LeBlanc, Richard, Sandhu, Irwindeep, White, Darrell, Belch, Andrew R., Reece, Donna E., Chen, Christine, Dolan, Sean, Lalancette, Marc, Louzada, Martha, Kew, Andrea, McCurdy, Arleigh, Monteith, Bethany, Reiman, Tony, McDonald, Gail, Sherry, Max, Gul, Engin, Chen, Bingshu E., Hay, Annette E.

Source: American journal of hematology. 96(5):552-560

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100119111007.0x000001&indx=1&recIds=ETOCvdc_100119111007.0x000001

Application of Value Frameworks to the Design of Clinical Trials: The Canadian Cancer Trials Group Experience

Authors: Del Paggio, Joseph C, Fundytus, Adam M, Hopman, Wilma M, Pater, Joseph L, Chen, Bingshu E, Brundage, Michael D, Hay, Annette E, Booth, Christopher M

Source: Journal of the National Cancer Institute. 113(10):1422-1428

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100131625135.0x000001&indx=1&recIds=ETOCvdc_100131625135.0x000001

Supportive care strategies in myelodysplastic syndromes and acute myeloid leukemia in older adults: a national survey of Canadian hematologists.

Authors: Blankstein, Anna R., Choi, Nora, Mozessohn, Lee, Sanford, David, Paulson, Kristjan, Rimmer, Emily, Houston, Donald S., Lother, Sylvain A., Mendelson, Asher, Garland, Allan, Zarychanski, Ryan, Hay, Annette E., Buckstein, Rena, Houston, Brett L.

Source: Annals of Hematology; Dec2024, Vol. 103 Issue 12, p5371-5376, 6p

Subject Terms: ACUTE myeloid leukemia, MEDICAL sciences, MYELODYSPLASTIC syndromes, TRANEXAMIC acid, OLDER people

Development and testing of a lymphoma clinical trial-specific frailty index: a secondary analysis of the NCIC-CTG LY.12 clinical trial.

Authors: Vijenthira, Abi, Li, Xinzhi, Crump, Michael, Hay, Annette E., Shepherd, Lois, Meyer, Ralph M., Djurfeldt, Marina, Chen, Bingshu E., Prica, Anca

Source: Leukemia & Lymphoma; Nov2024, Vol. 65 Issue 11, p1651-1658, 8p

Subject Terms: CLINICAL trials, STEM cell transplantation, NON-Hodgkin's lymphoma, FRAILTY, SECONDARY analysis

Drug-induced Thrombotic Microangiopathy with Concurrent Proteasome Inhibitor Use in the Treatment of Multiple Myeloma: A Case Series and Review of the Literature

Authors: Monteith, Bethany E., Venner, Christopher P., Reece, Donna E., Kew, Andrea K., Lalancette, Marc, Garland, Jocelyn S., Shepherd, Lois E., Pater, Joseph L., Hay, Annette E.

Source: In Clinical Lymphoma, Myeloma and Leukemia November 2020 20(11):e791-e800

Consensus Guidelines on the Diagnosis of Multiple Myeloma and Related Disorders: Recommendations of the Myeloma Canada Research Network Consensus Guideline Consortium

Authors: Côté, Julie, LeBlanc, Richard, Reiman, Anthony, Sebag, Michael, Song, Kevin W., Colasurdo, Gabriele, Del Col, Aldo, McMullen, David, Hay, Annette E., Laferriere, Nicole M.B., Robertson McCurdy, Arleigh B., Roy, Jean, Stakiw, Julie L., Trudel, Suzanne M., White, Darrell J., Loveys, Fraser W., Randell, Edward, Rizkalla, Kamilia S., Bergstrom, Debra J., Kotb, Rami, Louzada, Martha L., Sutherland, Heather J., Tavoularis, Sofia, Venner, Christopher P.

Source: In Clinical Lymphoma, Myeloma and Leukemia July 2020 20(7):e352-e367

IND.216: a phase II study of buparlisib and associated biomarkers, raptor and p70S6K, in patients with relapsed and refractory chronic lymphocytic leukemia

Authors: Assouline, Sarit, Amrein, Lilian, Aloyz, Raquel, Banerji, Versha, Caplan, Stephen, Owen, Carolyn, Hasegawa, Wanda, Robinson, Sue, Shivakumar, Sudeep, Prica, Anca, Peters, Anthea, Hagerman, Linda, Rodriguez, Laura, Skamene, Tanya, Panasci, Lawrence, Chen, Bingshu E., Hay, Annette E.

Source: Leukemia & lymphoma. 61(7):1653-1659

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100110727427.0x000001&indx=1&recIds=ETOCvdc_100110727427.0x000001

Canadian cancer trials group LY.17: A randomized phase II study evaluating novel salvage therapy pre‐autologous stem cell transplant in relapsed/refractory diffuse large B‐cell lymphoma—outcome of rituximab‐dose‐intensive cyclophosphamide, etoposide, cisplatin (R‐DICEP) versus R‐GDP

Authors: Stewart, Douglas A., Kuruvilla, John, Lee, David, Dudebout, Jill J., Chua, Neil, Larouche, Jean‐François, Baetz, Tara, Shafey, Mona, Abdel‐Samad, Nizar, Robinson, Sue, Fleury, Isabelle, Fraser, Graeme, Skrabek, Pamela, Kukreti, Vishal, Kelly, Jesse, Hay, Annette E., Shepherd, Lois E., Chen, Bingshu E., Crump, Michael

Source: British Journal of Haematology; Sep2024, Vol. 205 Issue 3, p881-890, 10p

Subject Terms: STEM cell treatment, SALVAGE therapy, CISPLATIN, RITUXIMAB, SURVIVAL rate, STEM cell transplantation

Understanding the patient perspective on research access to national health records databases for conduct of randomized registry trials

Authors: Avram, Robert, Marquis-Gravel, Guillaume, Simard, François, Pacheco, Christine, Couture, Étienne, Tremblay-Gravel, Maxime, Desplantie, Olivier, Malhamé, Isabelle, Bibas, Lior, Mansour, Samer, Parent, Marie-Claude, Farand, Paul, Harvey, Luc, Lessard, Marie-Gabrielle, Ly, Hung, Liu, Geoffrey, Hay, Annette E., Marc Jolicoeur, E.

Source: In International Journal of Cardiology 1 July 2018 262:110-116

A phase I study of romidepsin, gemcitabine, dexamethasone and cisplatin combination therapy in the treatment of peripheral T-cell and diffuse large B-cell lymphoma; the Canadian cancer trials group LY.15 study†

Authors: Reiman, Tony, Savage, Kerry J., Crump, Michael, Cheung, Matthew C., MacDonald, David, Buckstein, Rena, Couban, Stephen, Piliotis, Eugenia, Imrie, Kevin, Spaner, David, Shivakumar, Sudeep, Kuruvilla, John, Villa, Diego, Shepherd, Lois E., Skamene, Tanya, Winch, Chad, Chen, Bingshu E., Hay, Annette E.

Source: Leukemia & lymphoma. 60(4):912-919

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100098745343.0x000001&indx=1&recIds=ETOCvdc_100098745343.0x000001

Management and use of healthcare resources in patients with chronic lymphocytic leukemia initiating venetoclax in routine clinical practice.

Authors: Banerji, Versha, Aw, Andrew, Laferriere, Nicole, Abdel-Samad, Nizar, Peters, Anthea, Johnson, Nathalie A., Bernard, Marie-Pierre, Gopalakrishnan, Sathish, Bull, Sarah-Jane, Fournier, Pierre-André, Klil-Drori, Adi J., Hay, Annette E., Robinson, Sue, Owen, Carolyn

Source: Leukemia & Lymphoma; May2024, Vol. 65 Issue 5, p609-617, 9p

Subject Terms: CHRONIC lymphocytic leukemia, TUMOR lysis syndrome, VENETOCLAX, MEDICAL care, QUALITY of life, CANADIAN provinces

Geographic Terms: CANADA

Correlation of single arm versus randomised phase 2 oncology trial characteristics with phase 3 outcome

Authors: Monzon, Jose G., Hay, Annette E., McDonald, Gail T., Pater, Joseph L., Meyer, Ralph M., Chen, Eric, Chen, Bingshu E., Dancey, Janet E.

Source: In European Journal of Cancer November 2015 51(17):2501-2507

Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12

Authors: Kuruvilla, John ^*, MacDonald, David A., Kouroukis, C. Tom, Cheung, Matthew, Olney, Harold J., Turner, A. Robert, Anglin, Peter, Seftel, Matthew, Ismail, Walid Sabry, Luminari, Stefano, Couban, Stephen, Baetz, Tara, Meyer, Ralph M., Hay, Annette E., Shepherd, Lois, Djurfeldt, Marina S., Alamoudi, Sameer, Chen, Bingshu E., Crump, Michael

Source: In Blood 6 August 2015 126(6):733-738